10 Centers Share First Avon ‘Progress for Patients’ Grants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

BETHESDA, Maryland-Six initial breast cancer research grants totaling $2.5 million have been awarded through the National Cancer Institute-Avon Foundation’s Progress for Patients program to fund innovative translational science at 10 research institutions. The program administers a $20 million pledge from the Avon Foundation. The initial grants consist of $1.99 million from the Avon Foundation and $660,000 from NCI.

BETHESDA, Maryland—Six initial breast cancer research grants totaling $2.5 million have been awarded through the National Cancer Institute-Avon Foundation’s Progress for Patients program to fund innovative translational science at 10 research institutions. The program administers a $20 million pledge from the Avon Foundation. The initial grants consist of $1.99 million from the Avon Foundation and $660,000 from NCI.

Lead institutions for the six grants are the University of Alabama, Baylor College of Medicine, Fred Hutchinson Cancer Center, University of North Carolina at Chapel Hill, Duke University, and Dana Farber-Harvard Cancer Institute.

Articles in this issue
Tandem Transplants Increase CR, Reduce Treatment Mortality in Multiple Myeloma
Stereotactic Radiosurgery Benefits Brain Met Patients
Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Report
Tailored Messages Motivate Women to Get Mammograms
Chemo/Rituximab Is Effective as First-Line CLL Therapy
Preoperative Capecitabine/RT Downstages Rectal Cancer
Intraoperative Lymphatic Mapping Enhances Cancer Staging
Rituximab Ups Survival in Aggressive and Indolent NHL
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial
Lower Breast Cancer Survival in Hispanics: New Mexico Study
Concurrent Chemo/RT More Likely to Save Larynx
Rituximab Improves Paclitaxel/ Topotecan Salvage Efficacy in NHL
CT Growth Assessment Reliably Diagnoses Solid Lung Nodules
Fludarabine Combos Showing Efficacy in Lymphomas
EntreMed’s Thalidomide Analog in Phase I Multiple Myeloma Trial

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content
Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

Roman Fabbricatore
April 18th 2025
Article

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Optimizing Radiosurgery for CNS Tumors, Insights on Technology and Teamwork

Optimizing Radiosurgery for CNS Tumors, Insights on Technology and Teamwork

Ariana Pelosci
April 18th 2025
Article

William Kennedy, MD, discussed modern radiosurgery techniques, technology selection, and the multidisciplinary approach for treating complex CNS tumors.

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Tim Cortese
April 18th 2025
Article

Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.